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Research, and Health Technology Assessment in Central and Eastern
Europe, Western Asia, and AfricaDuring the organizational and functional development of the
International Society for Pharmacoeconomics and Outcomes
Research (ISPOR), more attention was paid to developing regions.
In addition to the traditional annual meetings in Western Europe
and North-America, the 1st Asia-Paciﬁc Conference and the 1st
Latin America Conference were organized in 2003 and 2007, respec-
tively. In addition to Value in Health, its well-established journal,
ISPOR introduced Value in Health Regional Issues (ViHRI), its new
independent, ofﬁcial scientiﬁc journal in 2012. Its 1st volume,
published in 2012, consisted of two issues covering the regions of
Asia [1,2] and Latin America [3,4]. As of 2013, a special issue has
been devoted to the regions of Central and Eastern Europe, Western
Asia, and Africa (CEEWAA). Countries eligible from Central and
Eastern Europe include Albania, Belarus, Bosnia and Herzegovina,
Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Latvia,
Lithuania, Montenegro, Poland, Republic of Moldova, Romania,
Russian Federation, Serbia, Slovakia, Slovenia, Ukraine, and The
Former Yugoslav Republic of Macedonia. Countries eligible from
Western Asia are Armenia, Azerbaijan, Bahrain, Cyprus, Georgia,
Iraq, Israel, Jordan, Kuwait, Lebanon, Occupied Palestinian Terri-
tory, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Turkey,
United Arab Emirates, and Yemen. All African countries are eligible.
The criteria of an article to be considered in ViHRI CEEWAA are
as follow: at least one of the authors of an article submitted to the
journal must reside in the region; when an article reporting on an
empirical study is submitted, it must include subjects from
population(s) in the region. For the ﬁrst CEEWAA issue of ViHRI,
54 manuscripts were submitted of which 24 have been accepted
for publication following a thorough review process.
The introduction of a special issue for the CEEWAA region of
ISPOR provides a great opportunity for scholars from these coun-
tries to publish their research ﬁndings and health policy reports in
an international scientiﬁc journal. Yet, it is very challenging to
include in one issue articles from a variety of regions. One should
bear in mind that countries of the CEEWAA region represent a
heterogeneous region with substantial differences and challenges
relating to country’s wealth (i.e., gross domestic product per
capita), political environment, population’s health status, health
care affordability, and spending. For example, the life expectancy
at birth for males is 72 years for the World Health Organization
(WHO) European Region, 67 years for the Eastern Mediterranean
Region, and 55 years for the African Region, while for females, the
values are 79, 70, and 58 years, respectively. The number of
physicians per 10,000 populations is 33.3 for the WHO European
Region, 10.8 for the Eastern Mediterranean Region, and 2.5 for therest: The authors have indicated that they have n
ial support: The authors have no other ﬁnancial rAfrican Region. The per-capita total expenditure on health (pur-
chasing power parity international $) is 2282 for the WHO
European Region, 326 for the Eastern Mediterranean Region, and
154 for the African Region [5].
The diversity of challenges in these countries could result in a
broader spectrum of published articles. While in some developed
countries, cutting of hospital beds or narrowing the health
insurance basic beneﬁt package represent key health policy
objectives, other countries try to establish a hospital system or
introduce a basic beneﬁt package for larger parts of their popula-
tion. Whatever is a current leading health policy issue in either a
nationwide or a local health care system, decision making should
rely on strong scientiﬁc evidence. In this decision-making process,
health-economics and outcomes research must play an important
role by informing decision makers on the costs and beneﬁts of
alternative medical interventions. Although publications from the
CEEWAA relating to pharmacoeconomics and outcomes research
are limited, current research topics cover health-economic ana-
lyses [6,7], coverage policy of new medical technologies [8,9],
pharmaceutical market analyses [10,11], burden of disease studies
[12], and budget constraints issues [13].
The current issue of ViHRI features articles from 15 different
countries and include economic analyses and patient-reported
outcomes on various disease areas such as cardiovascular dis-
eases, diabetes, cancer, and psychiatric conditions, as well as
clinical outcomes studies and health policy analyses. We hope
that both readers and policymakers will ﬁnd this issue informa-
tive and enriching.
Finally, we thank the ISPOR staff for initiating and supporting
this new journal and encourage scholars from ISPOR’s CEEWAA
countries to submit their research ﬁndings to ViHRI.
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